UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/045,178	01/11/2002	Noriyuki Kasahara	0072601-000005	7589
26138 Joseph R. Bake	7590 04/01/200 r. APC	9	EXAMINER	
Gavrilovich, Do	odd & Lindsey LLP		POPA, ILEANA	
4660 La Jolla V San Diego, CA	'illage Drive, Suite 750 92122	U	ART UNIT	PAPER NUMBER
<i>C 7</i>			1633	
			MAIL DATE	DELIVERY MODE
			04/01/2009	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
Interview Summary	10/045,178	KASAHARA ET	AL.
interview Summary	Examiner	Art Unit	
	ILEANA POPA	1633	
All participants (applicant, applicant's representative, PTO	personnel):		
(1) <u>ILEANA POPA</u> .	(3) <u>Joseph Baker</u> .		
(2) <u>Joseph Woitach</u> .	(4) <u>Noriyuki Kasahara; Dou</u>	ıglas Jolly.	
Date of Interview: 26 March 2009.			
Type: a)☐ Telephonic b)☐ Video Conference c)☑ Personal [copy given to: 1)☐ applicant 2	e)⊠ applicant's representative	•]	
Exhibit shown or demonstration conducted: d)⊠ Yes If Yes, brief description: <i>Applicant provided data demon</i>	e)⊡ No. ostrating the efficeincy and sta	bility of the clain	ned vecto.
Claim(s) discussed: All pending claims.			
Identification of prior art discussed: Ram et al. (Cancer Res 5,585,096); Murakami et al. (Gene, 1997, 202: 23-29).	:., 1993, 53: 83-88); Martuza e	et al. (U.S. Paten	t No.
Agreement with respect to the claims f) was reached. g	)∏ was not reached. h)⊠ N	I/A.	
Substance of Interview including description of the general reached, or any other comments: <u>Applicant submitted that a prior art because the prior art taught against inserting foreig vectors.</u> <u>Applicant was informed that his arguments and evalumitted.</u>	the claimed vector would not had genes into replication comp	nave been obvio Detent mammalia	us over the n retroviral
(A fuller description, if necessary, and a copy of the amend allowable, if available, must be attached. Also, where no callowable is available, a summary thereof must be attached	opy of the amendments that w		
THE FORMAL WRITTEN REPLY TO THE LAST OFFICE A NTERVIEW. (See MPEP Section 713.04). If a reply to the GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW DATE, OR THE SUBSTANCE OF THE INTERVIEW OF THE INTERVIEW OF THE SUBSTANCE OF TH	last Office action has already OF ONE MONTH OR THIRTY ERVIEW SUMMARY FORM, V	been filed, APP ' DAYS FROM T WHICHEVER IS	LICANT IS THIS LATER, TO
/lleana Popa/			